Market Place
Sourcing Support
Plus Therapeutics Wins Coverage for CNSide CSF Assay
28 Apr 2026 //
GLOBENEWSWIRE
Plus Therapeutics Restores Nasdaq Bid Price Compliance
21 Apr 2026 //
GLOBENEWSWIRE
Plus Therapeutics Names Goodman VP of Value Strategy
15 Apr 2026 //
GLOBENEWSWIRE
Plus Therapeutics Reports Nasdaq Inducement Grants
31 Mar 2026 //
GLOBENEWSWIRE
Plus Therapeutics Announces Reverse Stock Split
31 Mar 2026 //
GLOBENEWSWIRE
Plus Therapeutics Appoints Ron Andrews to Board
26 Mar 2026 //
GLOBENEWSWIRE
Plus Therapeutics To Unveil CNSide Cost Savings Data At ISPOR
19 Mar 2026 //
GLOBENEWSWIRE
Plus Therapeutics Unveils Results 2025 & Milestones for REYOBIQ
12 Mar 2026 //
GLOBENEWSWIRE
Plus Therapeutics Secures CPT Code for REYOBIQ
25 Feb 2026 //
GLOBENEWSWIRE
Plus Therapeutics To Host Business Update Conference Call
21 Jan 2026 //
GLOBENEWSWIRE
Plus Therapeutics Prices Upsized $15M Public Offering
14 Jan 2026 //
GLOBENEWSWIRE
Plus Therapeutics Expands Cnside Assay Platform In California
11 Dec 2025 //
GLOBENEWSWIRE
Plus Therapeutics Expands Cnside Team, Issues Inducement Grants
09 Dec 2025 //
GLOBENEWSWIRE
Plus Therapeutics Secures Humana Deal For CNSide Assay
20 Nov 2025 //
GLOBENEWSWIRE
Plus Therapeutics Receives 180-Day Nasdaq Bid Price Compliance
17 Nov 2025 //
GLOBENEWSWIRE
Plus Therapeutics Unveils Q3 Financials And Recent Achievements
30 Oct 2025 //
GLOBENEWSWIRE
Plus Therapeutics Secures $1.9m Payment From Cprit
22 Sep 2025 //
GLOBENEWSWIRE
Plus Therapeutics to Join at HC Wainwright Investment Conference
02 Sep 2025 //
GLOBENEWSWIRE
Plus Therapeutics Restores Nasdaq Listing Compliance
26 Aug 2025 //
GLOBENEWSWIRE
Plus Therapeutics Meets Nasdaq Rule With $2.5M Equity
15 Aug 2025 //
GLOBENEWSWIRE
Plus Therapeutics Unveils Promising CNSide Csf Assay Results
14 Aug 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q2 Financial Results and Business
14 Aug 2025 //
GLOBENEWSWIRE
Plus Therapeutics Updates on US Launch of CNSide® Diagnostic
31 Jul 2025 //
GLOBENEWSWIRE
Plus Therapeutics Gets $1.6M Advance Payment from CPRIT
23 Jul 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reveals REYOBIQ Results for Leptomeningeal
15 Jul 2025 //
GLOBENEWSWIRE
Plus Therapeutics to Present Two CNSide Studies at SNO/ASCO CNS
10 Jul 2025 //
GLOBENEWSWIRE
Plus Gets FDA OK for ReSPECT-LM Dose Trial in LM
30 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics Updates on CNSide Subsidiary
26 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics to Host Business Update and Call on June 26
25 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics FDA clears REYOBIQTM for Childhood Brain Cancer
25 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics Announces $15M Equity Financing Restructuring
24 Jun 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q1 Financial Results & Highlights
30 May 2025 //
GLOBENEWSWIRE
Plus Therapeutics Receives Nasdaq Deficiency Notice
23 May 2025 //
GLOBENEWSWIRE
Plus Therapeutics to Join D. Boral Capital Global Conference
08 May 2025 //
GLOBENEWSWIRE
Plus Therapeutics: Kyle Guse Joins Board of Directors
23 Apr 2025 //
GLOBENEWSWIRE
Plus Therapeutics Presents New Data on REYOBIQ in ReSPECT-LM Trial
15 Apr 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q4 and Full Year 2024 Financial Results
27 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name
20 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutic to Announce Q4 & Full Year 2024 Financial Results
19 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Regains Nasdaq Compliance On Equity Requirement
10 Mar 2025 //
GLOBENEWSWIRE
Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature
07 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Announces New Employment Inducement Grants
05 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Secures $15M in Private Placement
04 Mar 2025 //
GLOBENEWSWIRE
Plus Therapeutics Advances Rhenium (186Re) Obisbemeda For LM
26 Feb 2025 //
GLOBENEWSWIRE
Plus Therapeutics Names Dr. Michael As Chief Development Officer
20 Feb 2025 //
GLOBENEWSWIRE
Plus Therapeutics Secures $5.7M To Support Leptomeningeal Program
18 Feb 2025 //
GLOBENEWSWIRE
Plus Therapeutics Presents Positive ReSPECT-LM Ph 1 Data at SABCS
17 Dec 2024 //
GLOBENEWSWIRE
Plus Therapeutics Showcases ReSPECT-LM Ph 1 Data at SABCS 2024
04 Dec 2024 //
GLOBENEWSWIRE
Plus Expands Agreement with Telix for Rhenium-186 Supply
03 Dec 2024 //
GLOBENEWSWIRE
Plus Presents Phase 1 Data for Leptomeningeal at SNO Conference
25 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q3 2024 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics & SpectronRx Announce Radiotherapeutic Deal
06 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics to Announce Q3 Results & Host Call on Nov 14
05 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics Showcases Leptomeningeal Programs at SNO 2024
29 Oct 2024 //
GLOBENEWSWIRE
Plus Therapeutics Updates ReSPECT-GBM Trial at Neurosurgeons Meeting
01 Oct 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents ReSPECT-GBM Data At CNS Meeting
18 Sep 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q2 2024 Financial Results And Business Highlights
14 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents Trial Results At SNO/ASCO Conference
13 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents ReSPECT-LM Phase 1 Data At SNO/ASCO
12 Aug 2024 //
GLOBENEWSWIRE
